About Autolus Therapeutics

Autolus is a CAR T cell therapy company building a fully integrated platform to deliver life-changing treatments for patients with cancer and autoimmune diseases. The company applies extensive T cell programming capabilities to develop advanced autologous therapies, with a clinical-stage pipeline for hematological malignancies, solid tumors, and autoimmune indications. Founded in 2014 on technology pioneered at University College London, Autolus has grown to encompass proprietary manufacturing processes, a modular programming approach, and strong intellectual property. The team includes pioneers in T cell therapies and leaders in cancer immunotherapies committed to developing therapies offering substantial benefits over existing treatment.